Daraasad lagu daabacay khadka internetka ee Joornaalka Ururka Caafimaadka Maraykanka ee May 21st ayaa muujisay in tijaabooyin badan oo hidde-sidaha ah ee kansarka sanbabada ay gacan ka geysan karaan xulashada cilladaha hidde-socodka ee daaweynta la beegsanayo. Marka la barbardhigo bukaanada aan helin daawaynta la beegsaday, bukaanada qaata daawaynta u dhigma kansarka sanbabada waxay yeelan doonaan waqti dheer oo badbaado ah. Si kastaba ha ahaatee, tijaabooyin caafimaad oo aan kala sooc lahayn ayaa loo baahan yahay si loo xaqiijiyo in istiraatiijiyaddan daawaynta ay hagaajin karto badbaadada bukaanka iyo in kale.
The introduction of targeted therapy has changed the situation of lung cancer treatment by integrating buro genotyping with treatment decisions. adenocarcinoma is the most common type of lung cancer; 130,000 people are diagnosed with lung adenocarcinoma each year in the United States, and 1 million people are diagnosed with lung adenocarcinoma each year worldwide.
Macluumaadka asalka ah ee maqaalku wuxuu muujinayaa in inta jeer ee dhaqdhaqaaqa darawallada oncogene ee sambabada adenocarcinoma la filayo inay ka sarreeyaan 50%, iyo cilladaha unugyada unugyada ee darawalladani waxay muhiim u yihiin horumarinta kansarka. Darawaliintan waxaa lagu qeexay inay yihiin "firfircoon" sababtoo ah waxay u rogi karaan diidmo iyadoo la beegsanayo daroogooyinka bartilmaameedka ah goob kasta oo aan caadi ahayn oo ku jirta genome.
Dr. Mark G. Kris of the Memorial Sloan Kettering Cancer Center in New York et al. counted the frequency of carcinogenic drivers in patients with lung adenocarcinoma, and used this data to explore the proportion of patients who selected a certain targeted treatment together with overall survival . From 2009 to 2012, 14 centers in the Kansarka Sambabka Mutation Alliance recruited patients with metastatic lung adenocarcinoma and tested tumors in patients who met specific criteria for 10 oncogene driver factors. The study was published in JAMA (2014; doi: 10.1001 / jama.2014.3741).
Intii lagu guda jiray daraasadda, cilmi-baarayaashu waxay tijaabiyeen ugu yaraan 1 hiddo-wadaha burooyinka 1007 bukaan, waxayna tijaabiyeen 10 hiddo-sideyaal (bukaanno si buuxda u genotyped) oo ku saabsan burooyinka 733 bukaan. 733 ka mid ah bukaannada, 466 (64%) waxay heleen darawalka oncogene. 275 ka mid ah 1007 bukaan (28%) waxay u isticmaaleen natiijooyinkan si ay u doortaan daawaynta la beegsaday ama galaan tijaabooyin caafimaad.
Badbaadada dhexdhexaadka ah ee bukaanada 260 ee qaaday darawalka oncogene oo helay daawaynta daroogada la beegsaday waxay ahayd 3.5 sano; Badbaadada dhexdhexaadka ah ee bukaanada 318 ee qaaday darawalka oncogene laakiin aan qaadan daawaynta la beegsaday waxay ahayd 2.4 Sano; Badbaadada dhexdhexaadka ah ee 360 bukaan oo aan la helin darawal ayaa ahaa 2.1 sano.
The researchers came to the conclusion that multiple genetic testing can help physicians choose a method of treating kansarka sanbabada. Although patients with a certain target drug target driver gene will prolong survival after treatment, the design of this study cannot draw decisive conclusions about the difference in survival caused by oncogene driver.
Xigasho: Beerta Lilac
